Drug intelligence / Profile preview

EP-1300

Development stage: Phase 1
Lead developer: GemVax & Kael
Modality: DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

EP-1300 is a polyepitope DNA vaccine expressing 38 cytotoxic T cell epitopes and 16 helper T cell epitopes derived from Plasmodium falciparum antigens expressed predominantly in the liver phase of the parasite's life cycle. It was developed as a potential vaccine against P. falciparum malaria.

Beyond the preview

Go deeper on EP-1300.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EP-1300.

Explore the full profile